Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A national study has found that a significant proportion of clinically at-risk patients with certain immunocompromised or immunosuppressed conditions, mount a low, or undetectable, immune response after two doses of the same COVID-19 vaccine.

Needle going into an arm

The ongoing multi-centre OCTAVE study is evaluating the immune responses following COVID-19 vaccination in patients with immune-mediated inflammatory diseases such as cancer, inflammatory arthritis, diseases of the kidney or liver, or patients who are having a stem cell transplant. Initial data from the study have been published on the Lancet pre-print site

The study is led by the University of Glasgow and co-ordinated by the University of Birmingham’s Cancer Research UK Clinical Trials Unit. Researchers from Oxford University Hospitals (OUH) and the University of Oxford’s Nuffield Department of Medicine are leading the research involving patients with gastrointestinal diseases.

Read the full story on the University of Oxford website

Similar stories

Can humans hibernate?

Illuminating new TEDx Talk from Professor of Sleep Physiology Vladyslav Vyazovskiy

Athena Swan Gold Award success for Nuffield Department of Primary Care Health Sciences

The award reflects the Department’s commitment to representation, progression and success for all. It acknowledges the innovative policies and practices developed across the department and the detailed action plans for improvement.

RECOVERY trial team awarded MRC Impact Prize for Outstanding Team Impact

The Medical Research Council Prize Committee has awarded the RECOVERY trial team the MRC Impact Prize 2022 for Outstanding Team Impact.

Professor Sir Chris Whitty brings greater understanding of epidemics to Oxford

Chief Medical Officer of England Professor Sir Chris Whitty KCB FMedSci delivers the Sherrington Prize Lecture: Public Understanding of Science to an audience of Oxford staff and students.

Multiple Debilitating Pains – New global study shows the experience of Endometriosis is rooted in a person’s genetics

Researchers at the University of Oxford in collaboration with 25 teams across the world have published the largest study to date of the genetic basis of endometriosis.

Study shows delaying treatment for localised prostate cancer does not increase mortality risk

Active monitoring of prostate cancer has the same high survival rates after 15 years as radiotherapy or surgery, reports the largest study of its kind.